Disease Information
General Information of the Disease (ID: DIS00016)
Name |
Nongonococcal urethritis
|
---|---|
ICD |
ICD-11: 1A81
|
Resistance Map |
Type(s) of Resistant Mechanism of This Disease
ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Drug
Approved Drug(s)
1 drug(s) in total
Ciprofloxacin XR
Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
Aberration of the Drug's Therapeutic Target (ADTT) | ||||
Key Molecule: DNA gyrase subunit A (GYRA) | [1], [2] | |||
Resistant Disease | Ureaplasma parvum infection [ICD-11: 1A81.1] | |||
Molecule Alteration | Missense mutation | p.S83L |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli k-12 JM109 | 83333 | ||
Ureaplasma parvum serovar 3 isolates | 38504 | |||
Ureaplasma parvum serovar 6 isolates | 95660 | |||
Ureaplasma urealyticum isolates | 2130 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Quinolones are used for treating urogenital infections and interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and parC and parE genes for topoisomerase IV.Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. | |||
Key Molecule: DNA gyrase subunit A (GYRA) | [1], [2] | |||
Resistant Disease | Ureaplasma urealyticum infection [ICD-11: 1A81.2] | |||
Molecule Alteration | Missense mutation | p.S83L |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli k-12 JM109 | 83333 | ||
Ureaplasma parvum serovar 3 isolates | 38504 | |||
Ureaplasma parvum serovar 6 isolates | 95660 | |||
Ureaplasma urealyticum isolates | 2130 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Quinolones are used for treating urogenital infections and interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and parC and parE genes for topoisomerase IV.Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. | |||
Key Molecule: DNA topoisomerase 4 subunit A (PARC) | [1], [2] | |||
Resistant Disease | Nongonococcal urethritis [ICD-11: 1A81.3] | |||
Molecule Alteration | Missense mutation | p.S83W |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli k-12 JM109 | 83333 | ||
Ureaplasma parvum serovar 3 isolates | 38504 | |||
Ureaplasma parvum serovar 6 isolates | 95660 | |||
Ureaplasma urealyticum isolates | 2130 | |||
Ureaplasma parvum isolates | 38504 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Quinolones are used for treating urogenital infections and interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and parC and parE genes for topoisomerase IV.Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. | |||
Key Molecule: DNA topoisomerase 4 subunit A (PARC) | [1], [2] | |||
Resistant Disease | Nongonococcal urethritis [ICD-11: 1A81.3] | |||
Molecule Alteration | Missense mutation | p.S83P |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli k-12 JM109 | 83333 | ||
Ureaplasma parvum serovar 3 isolates | 38504 | |||
Ureaplasma parvum serovar 6 isolates | 95660 | |||
Ureaplasma urealyticum isolates | 2130 | |||
Ureaplasma parvum isolates | 38504 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Quinolones are used for treating urogenital infections and interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and parC and parE genes for topoisomerase IV.Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. | |||
Key Molecule: DNA topoisomerase 4 subunit A (PARC) | [1], [2] | |||
Resistant Disease | Nongonococcal urethritis [ICD-11: 1A81.3] | |||
Molecule Alteration | Missense mutation | ParC p.S83L+GyrB p.P462S |
||
Resistant Drug | Ciprofloxacin XR | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Escherichia coli k-12 JM109 | 83333 | ||
Ureaplasma parvum serovar 3 isolates | 38504 | |||
Ureaplasma parvum serovar 6 isolates | 95660 | |||
Ureaplasma urealyticum isolates | 2130 | |||
Ureaplasma parvum isolates | 38504 | |||
Experiment for Molecule Alteration |
Whole genome sequence assay | |||
Experiment for Drug Resistance |
Broth microdilution method assay | |||
Mechanism Description | Quinolones are used for treating urogenital infections and interact in bacteria with the type II topoisomerases DNA gyrase and topoisomerase IV, both of which are composed of two A and two B subunits; these subunits are encoded by the gyrA and gyrB genes for DNA gyrase and parC and parE genes for topoisomerase IV.Out of 28 clinical Ureaplasma strains, we isolated 9 with high MICs of quinolones and found a single parC gene mutation, resulting in the change S83L. |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.